

Zoliflodacin

Catalog No: **tcsc0016917**



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1620458-09-4

Formula:

$C_{22}H_{22}FN_5O_7$

Pathway:

Anti-infection;Cell Cycle/DNA Damage

Target:

Bacterial;DNA/RNA Synthesis

Purity / Grade:

>98%

Solubility:

DMSO : 140 mg/mL (287.21 mM; Need ultrasonic)

Alternative Names:

ETX0914;AZD0914

Observed Molecular Weight:


487.44

Product Description

Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione **bacterial DNA gyrase/topoisomerase** inhibitor. Zoliflodacin has potent *in vitro* antibacterial activity against Gram-positive and Gram-negative organisms, including *S. aureus* with the **MIC₉₀** of 0.25 µg/mL.

IC50 & Target: MIC90: 0.25 µg/mL (*S. aureus*)^[1]

In Vitro: Zoliflodacin has antibacterial activity against key Gram-positive (*Staphylococcus aureus*, *Staphylococcus epidermidis*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, and *Streptococcus agalactiae*), fastidious Gram-negative (*Haemophilus influenzae*, *Neisseria gonorrhoeae*), atypical (*Legionella pneumophila*), and anaerobic (*Clostridium difficile*) bacterial species, including isolates with known resistance to fluoroquinolones. The antibacterial activity of Zoliflodacin is shown to be via inhibition of DNA biosynthesis and accumulation of double-strand cleavages; this mechanism of action differs from those of other marketed antibacterial compounds, including fluoroquinolones. Zoliflodacin stabilizes and arrests the cleaved covalent complex of gyrase with double-strand broken DNA under permissive conditions and thus blocks religation of the double-strand cleaved DNA to form fused circular DNA^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!